Ano-genital human papillomavirus type 97 infection is detected in Canadian men but not women at risk or infected with the human immunodeficiency virus
1 Départements de Pathologie, Microbiologie-Infectiologie et Médecine, Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada
2 Immunodeficiency clinic, Division of Infectious Diseases, Toronto General Hospital, Toronto, ON, Canada
3 Department of obstetrics and gynecology, University of British Columbia, Vancouver, BC, Canada
4 Ontario Agency for Health Protection and Promotion, Public Health Laboratory, Toronto, ON, Canada
5 Sunnybrook Medical Centre, Toronto, ON, Canada
6 Direction de la Santé Publique de Montréal-Centre, Institut National de Santé Publique du Québec, Montréal, Québec, Canada
7 Laboratory of Molecular Virology, Institut de Recherches Cliniques de Montréal, Montréal, Québec, Canada
8 Départements de Biochimie et de microbiologie-Immunologie, Université de Montréal, Montréal, Québec, Canada
9 Division of Cancer Epidemiology, McGill University, Montreal, Québec, Canada
Virology Journal 2012, 9:243 doi:10.1186/1743-422X-9-243Published: 23 October 2012
Human papillomavirus type 97 (HPV97) DNA was detected in nearly 5% of anal samples collected from HIV-seropositive men living in Montreal, Canada. The rate of detection of HPV97 in the genital tract of Canadian women is unknown. Whether HPV97 is a local epidemic in HIV-seropositive men living in Montreal is also unknown. The prevalence of human papillomavirus type 97 (HPV97) was assessed in cervicovaginal cells from women living in Canada and in anal samples from HIV-seropositive men living in Toronto.
Cervicovaginal lavages collected from 904 women (678 HIV-seropositive, 226 HIV-seronegative) women living in Canada and anal cells collected from 123 HIV-seropositive men living in Toronto were tested for the presence of HPV97 with PCR. HPV97-positive samples were further tested by PCR-sequencing for molecular variant analysis to assess if all HPV97-positive men were infected with the same strain. All cervicovaginal samples were negative for HPV97. HPV97 was detected in anal samples from 6 HIV-seropositive men (4.9%, 95% confidence interval 2.0-10.5%), of whom five had high-grade and one had low-grade anal intraepithelial neoplasia, in addition to 2 to 8 HPV genital genotypes per sample. Four HPV97 variants were defined by four variation sites in the viral control region.
These findings indicate that HPV97 infects in the anal canal of HIV-seropositive men but is not detected in the genital tract of women.